Edema - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Edema - Pipeline Review, H1 2015', provides an overview of the Edema's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Edema and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Edema pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Edema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Edema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Edema Overview 6 Therapeutics Development 7 Pipeline Products for Edema - Overview 7 Pipeline Products for Edema - Comparative Analysis 8 Edema - Therapeutics under Development by Companies 9 Edema - Therapeutics under Investigation by Universities/Institutes 10 Edema - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Edema - Products under Development by Companies 15 Edema - Products under Investigation by Universities/Institutes 16 Edema - Companies Involved in Therapeutics Development 17 Apeptico Forschung und Entwicklung GmbH 17 Mirrx Therapeutics A/S 18 Otsuka Holdings Co., Ltd. 19 Edema - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 AP-301 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BC-1215 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CD5-2 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Synthetic Peptides for Edema - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 tolvaptan - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 X-0002 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Edema - Recent Pipeline Updates 38 Edema - Dormant Projects 41 Edema - Product Development Milestones 42 Featured News & Press Releases 42 Jan 18, 2013: Apeptico's AP301 Receives US And EU Orphan Drug Designation For Treatment Of High Altitude Pulmonary Oedema 42 Jun 29, 2012: Apeptico Initiates Phase II Trial With AP301 In Patients With Pulmonary Oedema 42 Apr 11, 2011: APEPTICO Initiates Phase I Trial With AP301 In Pulmonary Oedema 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables Number of Products under Development for Edema, H1 2015 7 Number of Products under Development for Edema - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Comparative Analysis by Unknown Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Edema - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2015 17 Edema - Pipeline by Mirrx Therapeutics A/S, H1 2015 18 Edema - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Edema Therapeutics - Recent Pipeline Updates, H1 2015 38 Edema - Dormant Projects, H1 2015 41
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.